Immunological Phenotype of Desmoid-fibromatosis-affected Patients.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano

About this trial

This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.

Eligibility criteria

Qualifiers

Patients with primary sporadic desmoid-type fibromatosis with measurable disease under active surveillance

Patients with primary sporadic desmoid-type fibromatosis with measurable disease receiving systemic treatment.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

200 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Lead sponsor

Campus Biomedico - Roma

Collaborator

Candiolo Cancer Institute - IRCCS

Collaborator

Azienda Ospedaliero-Universitaria Careggi

Collaborator

Azienda USL Toscana Centro

Collaborator

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

Collaborator

Erasmus University Rotterdam

Collaborator

Istituto Oncologico Veneto IRCCS

Collaborator